HR-Related Coronavirus Q&A: Our Answers to Your Questions
Client Alert | 1 min read | 04.21.20
We have drafted an ‘HR-Related Coronavirus Q&A’ in response to recent developments, and we thought that it might be of interest to you. You will find this Q&A here. In it, we take a look at our clients’ most commonly asked questions regarding the impact of the virus.
The questions and answers in this Q&A are of course of a general nature and should not be considered to be comprehensive legal advice on specific questions and/or cases. Do not hesitate to contact our team if you have any specific questions and/or would like any advice with regard to a concrete situation.
You will also find ‘Coronavirus Workplace Guidelines’ for US employers, which include useful tips and recommendations of a general reach as well (EU-based employers may disregard the US-specific guidelines).
Our team will continue to closely monitor developments and keep you posted.
Contacts
Insights
Client Alert | 6 min read | 04.29.26
CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)
On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies.
Client Alert | 8 min read | 04.27.26
Client Alert | 5 min read | 04.27.26
Drift Protocol Exploit: Why “Social Trust” Is the Newest Cybersecurity Gap
Client Alert | 4 min read | 04.27.26
Gaming Addiction Litigation: Turner v. Epic Games & Roblox and What It Means for the Industry
